Volume 28, Number 12—December 2022
Research Letter
Omicron BA.5 Neutralization among Vaccine-Boosted Persons with Prior Omicron BA.1/BA.2 Infections
Table
Characteristics of persons with and without Omicron BA.1/BA.2 breakthrough infection who received COVID-19 vaccines and booster doses, Denmark*
Characteristics | Vaccines and booster | Vaccines, booster, and Omicron breakthrough |
---|---|---|
Total no. persons |
24 |
12 |
Sex, no. (%) | ||
F | 17 (70.8) | 8 (66.6) |
M |
7 (29.2) |
4 (33.4) |
Median age, y (IQR) |
41 (32–51) |
47 (40–50) |
Median no. days (IQR) between vaccination, infection, and sampling | ||
Between first and second dose | 29 (27–36) | 28 (26–34) |
Between second and third dose | 152 (42–199) | 200 (159–228) |
Between third dose and sampling | 29 (23–34) | 90 (77–143) |
Between third dose and infection | NA | 55 (31–109) |
Between infection and sampling | NA | 33 (24–38) |
*Participants received 3 doses of BNT162b2 (Pfizer-BioNTech, https://www.pfizer.com), 2 initial vaccines and a booster dose. IQR, interquartile range; NA, not applicable